Paeonol attenuates Substance P-induced urticaria by inhibiting Src kinase phosphorylation in mast cells

• Published in: Cellular immunology 2023-07, Vol.388-389, p.104728-104728, Article 104728
• Main Authors: Ding, Yuanyuan, Dang, Baowen, Zhang, Yonghui, Hu, Shiting, Wang, Yuejin, Zhao, Chenrui, Zhang, Tao, Gao, Zijun
• Format: Article
• Language: English
• Subjects: Anaphylaxis - drug therapy; Animals; Cell Degranulation; Chemokines - metabolism; Chronic Urticaria - metabolism; Cytokines - metabolism; Inhibitor; Mast cells; Mast Cells - metabolism; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Paeonol; Phosphatidylinositol 3-Kinases - metabolism; Phosphorylation; Src; src-Family Kinases - metabolism; Substance P - metabolism; Substance P - pharmacology; Substance P - therapeutic use; Urticaria; Urticaria - metabolism
• ISSN: 0008-8749; 1090-2163
• DOI: 10.1016/j.cellimm.2023.104728

The molecular mechanism how Paeonol might prevent MRGPRX2-induced CU. [Display omitted] •Paeonol have the therapeutic effect in substance P induced urticaria model.•Paeonol regulate the downstream signaling pathway of MRGPRX2 in mast cells.•Paeonol attenuates substance P induced urticaria via Src kinase in mast cells. Treatment of chronic urticaria is challenging, the discovery of effective therapeutic drugs is urgently in demand. To study the effect and mechanism of Paeonol targeting mast cells and its therapeutic effect on chronic urticaria. Study design: We developed a chronic urticaria model in vivo and mast cell model in vitro examined the effect of Paeonol in the treatment of chronic urticaria and its mechanism of action in mast cells. The anti-anaphylactoid effect of Paeonol was evaluated in PCA and systemic anaphylaxis models. The treatment role of Paeonol was studied in urticaria model. The release of cytokines and chemokines was measured using enzyme immunoassay kits. Western blot analysis was conducted to investigate phosphorylation of Src, PI3K, and PLC. In vitro kinase assays were conducted to investigate the kinase activity of Lyn, PLC, PI3K and Src. In our study, Paeonol was able to attenuate evans blue leakage, serum histamine and chemokine release in a passive skin allergic reaction model. Simultaneously, Paeonol inhibited vasodilation and mast cell degranulation in C57BL/6 mice. Further research found that Paeonol alleviated symptoms such as erythema and rash in the Substance P-induced urticaria model, this is accompanied by inhibiting the release of related inflammatory factors. Validation experiments on mast cells in vitro found that Paeonol inhibited the activation of Src-PI3K/Lyn-PLC-NF-κB signaling pathway by crosslinking with Src kinase. Moreover, calcium influx, mast cell degranulation, cytokines generation and chemotaxis were reduced in LAD2 cells. Molecular docking experiments revealed that Paeonol is a specific antagonist targeting Src kinase in the treatment of skin diseases such as urticaria. Paeonol, a herb-derived phenolic compound, can provide drug candidate for developing new drug in treatment of skin disease such as urticaria. In this study, we primarily examined the effect of Paeonol in the treatment of chronic urticaria and its mechanism of action in mast cells. Interestingly, Paeonol was found to regulate Src kinase activity downstream of MRGPRX2 triggered signaling cascade in mast cells. Therefore, this plant-derived